Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

Ioannis K. Zervantonakis; Claudia Iavarone; Hsing-Yu Chen; Laura M. Selfors; Sangeetha Palakurthi; Joyce F. Liu; Ronny Drapkin; Ursula Matulonis; Joel D. Leverson; Deepak Sampath; Gordon B. Mills; Joan S. Brugge

doi:10.1038/s41467-017-00263-7

Nature Communications (Aug 2017)

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

Ioannis K. Zervantonakis,
Claudia Iavarone,
Hsing-Yu Chen,
Laura M. Selfors,
Sangeetha Palakurthi,
Joyce F. Liu,
Ronny Drapkin,
Ursula Matulonis,
Joel D. Leverson,
Deepak Sampath,
Gordon B. Mills,
Joan S. Brugge

Affiliations

Ioannis K. Zervantonakis: Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School
Claudia Iavarone: Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School
Hsing-Yu Chen: Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School
Laura M. Selfors: Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School
Sangeetha Palakurthi: Belfer Center for Applied Cancer Research, Dana Farber Cancer Institute
Joyce F. Liu: Department of Medical Oncology, Dana Farber Cancer Institute
Ronny Drapkin: Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine
Ursula Matulonis: Department of Medical Oncology, Dana Farber Cancer Institute
Joel D. Leverson: Oncology Development, AbbVie, Inc
Deepak Sampath: Translational Oncology, Genentech
Gordon B. Mills: Department of Systems Biology, MD Anderson Cancer Center
Joan S. Brugge: Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School

DOI: https://doi.org/10.1038/s41467-017-00263-7
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 13

Abstract

Read online

High-grade serous ovarian cancers (HGS-OvCa) frequently develop chemotherapy resistance. Here, the authors through a systematic analysis of proteomic and drug response data of 14 HGS-OvCa PDXs demonstrate that targeting apoptosis regulators can improve response of these tumors to inhibitors of the PI3K/mTOR pathway.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal